These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3235705)

  • 1. Persistence of neuroleptic drugs in plasma and body tissue.
    Pajari KL
    J Clin Psychopharmacol; 1988 Dec; 8(6):446. PubMed ID: 3235705
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute dystonia during fixed-dose neuroleptic treatment.
    Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
    J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentration of depot neuroleptics in tardive dyskinesia.
    Fairbairn AF; Rowell FJ; Hui SM; Hassanyeh F; Robinson AJ; Eccleston D
    Br J Psychiatry; 1983 Jun; 142():579-83. PubMed ID: 6882980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum calcium and magnesium levels in chronic schizophrenics.
    Athanassenas G; Papadopoulos E; Kourkoubas A; Tsitourides S; Gabriel J; Hoïdas S; Frangos E
    J Clin Psychopharmacol; 1983 Aug; 3(4):212-6. PubMed ID: 6886033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
    Linn GS; Lifshitz K; O'Keeffe RT; Lee K; Camp-Lifshitz J
    Psychopharmacology (Berl); 2001 Jan; 153(3):285-94. PubMed ID: 11271400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnosis of rapid abnormal involuntary movements associated with fluphenazine decanoate.
    Glazer WM; Moore DC
    J Nerv Ment Dis; 1980 Jul; 168(7):439-41. PubMed ID: 7400795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
    Chouinard G; Annable L; Ross-Chouinard A; Kropsky ML
    J Clin Psychiatry; 1979 Mar; 40(3):147-52. PubMed ID: 33969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome due to depot fluphenazine.
    Grunhaus L; Sancovici S; Rimon R
    J Clin Psychiatry; 1979 Feb; 40(2):99-100. PubMed ID: 762037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychophamacological treatment.
    Marriott P
    Schizophr Bull; 1976; 2(4):505-6. PubMed ID: 1019592
    [No Abstract]   [Full Text] [Related]  

  • 18. High neuroleptic plasma levels in patients manifesting supersensitivity psychosis.
    Chouinard G; Creese I; Boisvert D; Annable L; Bradwejn J; Jones B
    Biol Psychiatry; 1982 Jul; 17(7):849-52. PubMed ID: 7115836
    [No Abstract]   [Full Text] [Related]  

  • 19. Abnormal involuntary movements in patients on long-acting neuroleptics.
    Oyewumi LK; Lapierre YD; Gray R; Batth S; Gelfand R
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):719-23. PubMed ID: 6141614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.